

Product Update:

etravirine 25mg, 100mg, 200mg tablets (Intelence®) (No. 901/13)

Janssen-Cilag

09 August 2013

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

etravirine (Intelence®) is accepted for restricted use within NHS Scotland.

Indication under review: in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age.

SMC restriction: to be prescribed under the supervision of specialists in paediatric HIV.

SMC has previously accepted etravirine for use in combination with a boosted protease inhibitor and other antiretroviral medicinal products for the treatment of HIV-1 infection in antiretroviral treatment experienced adult patients. Etravirine is listed in the British National Formulary for Children 2012-2013 for the treatment of HIV infection.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 13 June 2013.

**Vice Chairman,
Scottish Medicines Consortium**

Published 09 September 2013